Tonix Pharmaceuticals TNX-1500 monoclonal antibody published in American Journal of Transplantation
New York
|
April 24, 2023 11:34 AM Eastern Daylight Time
Tonix Pharmaceuticals CEO Seth Lederman joins Proactive's Natalie Stoberman to share the findings of two publications in the American Journal of Transplantation that demonstrate how the company's TNX-1500 monoclonal antibody product candidate aided in the prevention of organ rejection for kidney and heart transplants.
Lederman says these animal studies found that TNX-1500 retains activity to prevent rejection and preserve graft function. He adds that Tonix expects to start a first-in-human Phase 1 study in the second quarter of 2023 of TNX-1500 for prophylaxis of organ rejection in adult patients receiving a kidney transplant.
Contact Details
Proactive Studio
+1 347-449-0879
